Repare Therapeutics Inc. (RPTX)
NASDAQ: RPTX · Real-Time Price · USD
2.870
+0.030 (1.06%)
Nov 21, 2024, 11:25 AM EST - Market open
Repare Therapeutics Employees
Repare Therapeutics had 179 employees as of December 31, 2023. The number of employees decreased by 1 or -0.56% compared to the previous year.
Employees
179
Change (1Y)
-1
Growth (1Y)
-0.56%
Revenue / Employee
$371,642
Profits / Employee
-$469,542
Market Cap
122.01M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 179 | -1 | -0.56% |
Dec 31, 2022 | 180 | 28 | 18.42% |
Dec 31, 2021 | 152 | 50 | 49.02% |
Dec 31, 2020 | 102 | 38 | 59.38% |
Dec 31, 2019 | 64 | - | - |
Related Stocks
Company Name | Employees |
---|---|
American Well | 1,104 |
Protalix BioTherapeutics | 208 |
TriSalus Life Sciences | 112 |
Cabaletta Bio | 103 |
Vigil Neuroscience | 69 |
Outlook Therapeutics | 24 |
Avalo Therapeutics | 19 |
Context Therapeutics | 5 |
RPTX News
- 9 days ago - Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib - Business Wire
- 14 days ago - Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results - Business Wire
- 4 weeks ago - Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial - Business Wire
- 5 weeks ago - Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor - Business Wire
- 7 weeks ago - Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting - Business Wire
- 2 months ago - Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers - Business Wire
- 2 months ago - Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024 - Business Wire
- 2 months ago - Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data - Seeking Alpha